These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37455125)

  • 1. [Expert consensus on newborn screening for spinal muscular atrophy (2023 edition)].
    ;
    Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2075-2081. PubMed ID: 37455125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go.
    Dangouloff T; Vrščaj E; Servais L; Osredkar D;
    Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies.
    Angilletta I; Ferrante R; Giansante R; Lombardi L; Babore A; Dell'Elice A; Alessandrelli E; Notarangelo S; Ranaudo M; Palmarini C; De Laurenzi V; Stuppia L; Rossi C
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Approaches and Practical Recommendations in Patient Care Identified with 5q Spinal Muscular Atrophy through Newborn Screening.
    Romanelli Tavares VL; Mendonça RH; Toledo MS; Hadachi SM; Grindler CM; Zanoteli E; Marques W; Oliveira ASB; Breinis P; Morita MDPA; França MC
    Genes (Basel); 2024 Jun; 15(7):. PubMed ID: 39062637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency.
    Butterfield RJ
    Semin Pediatr Neurol; 2021 Jul; 38():100899. PubMed ID: 34183144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective.
    Balaji L; Farrar MA; D'Silva AM; Kariyawasam DS
    Expert Rev Neurother; 2023; 23(7):571-586. PubMed ID: 37227306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands.
    Velikanova R; van der Schans S; Bischof M; van Olden RW; Postma M; Boersma C
    Value Health; 2022 Oct; 25(10):1696-1704. PubMed ID: 35963838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus).
    Pitarch Castellano I; Cabrera-Serrano M; Calvo Medina R; Cattinari MG; Espinosa García S; Fernández-Ramos JA; García Campos O; Gómez-Andrés D; Grimalt Calatayud MA; Gutiérrez Martínez AJ; Ibáñez Albert E; Kapetanovic García S; Madruga-Garrido M; Martínez-Moreno M; Medina Cantillo J; Melián Suárez AI; Moreno Escribano A; Munell F; Nascimento Osorio A; Pascual-Pascual SI; Povedano M; Santana Casiano IM; Vázquez-Costa JF
    Neurologia (Engl Ed); 2022 Apr; 37(3):216-228. PubMed ID: 35241415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implementation of newborn screening for spinal muscular atrophy: the Australian experience.
    Kariyawasam DST; Russell JS; Wiley V; Alexander IE; Farrar MA
    Genet Med; 2020 Mar; 22(3):557-565. PubMed ID: 31607747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era.
    Zettler B; Estrella E; Liaquat K; Lichten L
    J Genet Couns; 2022 Jun; 31(3):803-814. PubMed ID: 35037741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations.
    McMillan HJ; Kernohan KD; Yeh E; Amburgey K; Boyd J; Campbell C; Dowling JJ; Gonorazky H; Marcadier J; Tarnopolsky MA; Vajsar J; MacKenzie A; Chakraborty P
    Can J Neurol Sci; 2021 Jul; 48(4):504-511. PubMed ID: 33059774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expert consensus on preimplantation genetic testing for spinal muscular atrophy].
    The Expert Consensus Group For Preimplantation Genetic Testing For Spinal Muscular Atrophy ; Yan L; Zhu X; Huang J; Qiao J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Feb; 39(2):129-134. PubMed ID: 35076905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Room to improve: The diagnostic journey of Spinal Muscular Atrophy.
    Carter M; Tobin A; Coy L; McDonald D; Hennessy M; O'Rourke D
    Eur J Paediatr Neurol; 2023 Jan; 42():42-46. PubMed ID: 36525883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment.
    Nishio H; Niba ETE; Saito T; Okamoto K; Takeshima Y; Awano H
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early diagnosis of spinal muscular atrophy].
    Born AP; Werlauff U
    Ugeskr Laeger; 2021 Dec; 183(51):. PubMed ID: 34981731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal Muscular Atrophy: Past, Present, and Future.
    Ross LF; Kwon JM
    Neoreviews; 2019 Aug; 20(8):e437-e451. PubMed ID: 31371553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond.
    Groulx-Boivin E; Osman H; Chakraborty P; Lintern S; Oskoui M; Selby K; Van Caeseele P; Wyatt A; McMillan HJ
    Can J Neurol Sci; 2024 Mar; 51(2):203-209. PubMed ID: 36892082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why should a 5q spinal muscular atrophy neonatal screening program be started?
    Becker MM; Nardes F; Dangouloff T; Servais L; Araujo APQC; Gurgel-Giannetti J
    Arq Neuropsiquiatr; 2024 Oct; 82(10):1-9. PubMed ID: 39396519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy.
    Zanoteli E; Araujo APQC; Becker MM; Fortes CPDD; França MC; Machado-Costa MC; Marques W; Matsui C; Mendonça RH; Nardes F; Oliveira ASB; Pessoa ALS; Saute JAM; Sgobbi P; Van der Linden H; Gurgel-Giannetti J
    Arq Neuropsiquiatr; 2024 Jan; 82(1):1-18. PubMed ID: 38316428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening.
    Weng WC; Hsu YK; Chang FM; Lin CY; Hwu WL; Lee WT; Lee NC; Chien YH
    Genet Med; 2021 Feb; 23(2):415-420. PubMed ID: 33033402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.